|
|
| Contemporary Techniques in Transurethral Resection of Bladder Tumor, An Educational Course |
| Max Kates, MD |
| Sam Chang is joined by Max Kates to discuss the upcoming course offered at the American Urological Association (AUA) 2023 annual meeting titled, “Contemporary Techniques in Transurethral Resection of Bladder Tumor.” |
|
|
|
|
|
|
|
|
|
|
|
|
Reduction in the Risk of Recurrence with the Use of Blue Light Cystoscopy Use Among Patients with Non-Muscle Invasive Bladder Cancer In An Equal Access Setting
|
Stephen Williams, MD, MS, FACS
Sam Chang is joined by Stephen Williams to discuss the impact of Blue Light Cystoscopy use among patients with non-muscle invasive bladder cancer in an equal access setting, specifically the Veterans Affairs system.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
What to Expect from the Upcoming 2023 American Urological Association Annual Meeting
|
|
|
|
| Friday, April 28 |
| Plenary Session - 7:30-11:30 CST
|
|
|
|
|
|
State-of-the-Art Lecture: Histologic Subtypes in Renal Cell Carcinoma: Comparing and Contrasting Different Treatment Pathways/Options
Presented By: Brian Matthew Shuch, MD
|
|
|
|
|
AUA Guidelines: Early Detection of Prostate Cancer
Presented By: John Thomas Wei, MD
|
|
|
|
|
| Bladder Cancer: Non-Invasive I (MP08) - 9:30-11:30 CST
|
|
|
|
|
|
Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naive and Previously Treated Intermediate-risk Non-muscle Invasive Bladder Cancer
Presented By: Ian M. McElree, BS, MS
|
|
|
|
|
The Role of Flexible Blue Light Cystoscopy in Surveillance of Non-muscle Invasive Bladder Cancer. Results From a Nordic Registry
Presented By: Karsten Zieger, MD, PhD
|
|
|
|
|
Comparison of Intravesical Therapy and Surgery as Treatment Options for Recurrent Bladder Cancer (Cisto): Collection of Patient-reported Outcomes
Presented By: John Gore, MD, MS, FACS
|
|
|
|
|
| Prostate Cancer: Advanced (Including Drug Therapy) I (MP11) - 9:30-11:30 AM CST
|
|
|
|
|
|
Treatment Duration and Long-term Safety and Tolerability With Darolutamide in Nonmetastatic Castration-resistant Prostate Cancer (nmCRPC): Aramis Rollover Study
Presented By: Neal Shore, MD, FACS
Prostate-Specific Antigen Analyses in Propel: Abiraterone and Olaparib Versus Abiraterone and Placebo as First-line Therapy for Metastatic Castration-resistant Prostate Cancer
Presented By: Fred Saad, MD, FRCS
|
|
|
|
|
|
|
|
|
|
| Health Services Research: Practice Patterns, Quality of Life & Shared Decision Making I (MP19) - 3:30-5:30 PM CST
|
|
|
|
|
|
Impact of Social Vulnerability on Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer
Presented By: Rishi Sekar, MD
|
|
|
|
|
| Bladder Cancer: Invasive I (PD09) - 1:00-3:00 PM CST
|
|
|
|
|
|
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes From Javelin Bladder 100 in Subgroups Defined by Response to 1l Chemotherapy
Presented By: Begoña Valderrama
|
|
|
|
|
The Use of 68ga-fap-2286 Pet Imaging in Patients With Localized Bladder Cancer
Presented By: Domenique Escobar, MD
|
|
|
|
|
| Plenary Session - 1:00-2:30 PM CST |
|
|
|
|
|
AUA Guidelines: Upper Tract Urothelial Carcinoma (UTUC)
Presented By: Jonathan Andrew Coleman, MD
|
|
|
|
|
AUA Guidelines: Early Detection of Prostate Cancer
Presented By: John Wei, MD
|
|
|
|
|
Panel Discussion: Management of Upper Tract Urothelial Carcinoma
Presented By: Surena Matin, MD, Jay Raman, MD, FACS, Tomonori Habuchi, MD, Sima Porten, MD, FACS, MPH
|
|
|
|
|
| Saturday, April 29 |
| Bladder Cancer: Non-Invasive II (PD13) - 7:00-9:00 AM CST |
|
|
|
|
|
Core1: Phase 2 Single Arm Study of Cg0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
Presented By: Roger Li, MD
|
|
|
|
|
| Plenary Session - 7:45-11:35 AM CST
|
|
|
|
|
|
EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-Risk Biochemically Recurrent Prostate Cancer
Presented By: Neal Shore, MD, FACS
|
|
|
|
|
| Prostate Cancer: Advanced (including Drug Therapy) III (PD16) - 9:30-11:30 AM CST |
|
|
|
|
|
Examining Testosterone Recovery in Androgen Deprivation Therapy for Prostate Cancer
Presented By: Mark Preston, MD, MPH
Real World Characterization of Patients Receiving Relugolix or Androgen Deprivation Therapy Injections in Combination With Oral Anti-androgens in 2021 (the Real ADT Oral Study): Analysis From a US EMR Database
Presented By: Jason Hafron, MD
Real-World Outcomes Among Men With Nonmetastatic Castration-sensitive Biochemical Recurrence After Definitive Therapy With Short PSA Doubling Time Receiving Early Secondary Treatment
Presented By: Stephen Freedland, MD
|
|
|
|
|
|
|
|
|
|
| Sunday, April 30 |
| Late-Breaking Abstracts II - Cancer - 1:00-3:00 PM CST |
|
|
|
|
|
Biochemical Recurrence of Localized Prostate Cancer Originating From the Transition Versus Peripheral Zone: a Systematic Review and Meta-analysis
Presented By: Shijie Jin, MD
|
|
|
|
|
First Results From Sunrise-1 in Patients With BCG Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer Receiving Tar-200 in Combination With Cetrelimab, Tar-200, or Cetrelimab Alone
Presented By: Sia Daneshmand, MD
|
|
|
|
|
Outcomes and Genomic Characteristics of Newly Diagnosed High Grade Ta Papillary Urothelial Carcinoma Treated with Intravesical Chemotherapy vs Bacillus Calmette Guerin (BCG): A Comparative Study During the BCG Shortage
Presented By: Song Jiang
|
|
|
|
|
Psycho-social Distress and Quality of Life in Patients after Radical Cystectomy – One Year Follow-Up in 842 German Patients
Presented By: Henning Bahlburg, MD
|
|
|
|
|
Results From the Extended Follow-up in Patients With Muscle-invasive Bladder Cancer in the Checkmate 274 Trial
Presented By: Matthew Milowsky, MD, FASCO
|
|
|
|
|
Updated Progression-Free Survival from PRESTO: a Phase 3 Randomized Study of Androgen Annihilation for High-Risk Biochemically Relapsed Prostate Cancer (AFT-19)
Presented By: Scott Eggener, MD
|
|
|
|
|
Is Learning Curve Important While Performing PSMA-PET? Analysis of Detection Rate According to Gleason Score and PSA Level in Two Timeframes at a Brazilian High-Volume Center
Presented By: Paulo Lages, MD, FACS
|
|
|
|
|
| Bladder Cancer Forum - 2:00-5:00 PM CST |
|
|
|
|
|
Intermediate Risk NMIBC: Surveillance and Treatment Challenges
Presented By: Paolo Gontero, MD and Gary David Steinberg, MD
|
|
|
|
|
Optimal TURBT: Do Skilled Urologists Really Need PDD?
Presented By: Trinity Bivalacqua, MD, PHD and Michael S. Cookson, MD, FACS
|
|
|
|
|
Pathology or 'Markers': What is More Important?
Presented By: Charles Guo, MD and David McConkey, PhD
|
|
|
|
|
|
